

# Product Safety Data Sheet

This Product Safety Data Sheet contains information concerning the potential risks to those involved in handling, transporting, and working with the product, as well as describing potential risks to the consumer and the environment. This information must be made available to those who may come into contact with the product or are responsible for the use of the product.

## **SECTION 1: Identification of the substance/mixture and of the company/undertaking**

---

### **1.1 Product identifier**

Raksa CBD Full spectrum 1%

Product number: RS-ED-01

Name of common ingredients glossary / Other names:

Cannabidiol derived from extract of Cannabis (Hemp)

Purity: 1% concentrate by weight in MCT oil (see section 3.1)

### **1.2 Relevant identified uses of the substance or mixture and uses advised against**

Identified uses: Raw material for production of substances and formulations, cosmetics and consumable goods

### **1.3 Details of the supplier of the safety data sheet**

**GTG Plant Factory Co., Ltd.**

99/1 Soi Sukhumvit 36 (Sansabai), Sukhumvit Road, Klongton Subdistrict, Khlong Toei District, Bangkok 10110 Thailand

### **1.4 Emergency telephone number**

Tel: +66 (0) 2002 8007

Hours: 09:00h to 17:30h, Monday to Friday

support@gtg.co.th

## **SECTION 2: Hazards Identification**

### **2.1 Classification of the substance or mixture**

Not Classified, no dangerous substance or mixture according to Regulation (EC) No. 1272/2008.

This substance is not classified as dangerous according to Directive 67/548/EEC.

### **2.2 Label elements**

The product does not require special labelling according to EC directives or the respective Thai laws.

### **2.3 Other hazards**

None

#### **GHS Precautions Statements**

P101 If medical advice is needed, have product container or label at hand.

P102 Keep out of reach of children.

P202 Do not handle until all safety precautions have been read and understood.

P261 Avoid breathing dust/fume/gas/mist/vapours/spray

P263 Avoid contact during pregnancy/while nursing.

P273 Avoid release to the environment.

P305 IF IN EYES: rinse with plenty of water.

P314 Get Medical advice/attention if you feel unwell.

P332 + P313 IF skin irritation occurs: Get medical advice/attention.

This product is not a psychotropic drug and does not have a psychoactive effect.

GHS: Global Harmonized System of Classification and Labelling of Chemicals

### Section 3: COMPOSITION/Information of Ingredients

#### 3.1 Substances/mixture of substances

Concentrated cannabidiol extract (CBD) by supercritical carbon dioxide (CO<sub>2</sub>) extraction in mixture with MCT oil.

Compound	Mass fraction	CAS No.	Hazard level
MCT oil	96 – 98%	538-23-8	None
Concentrated cannabidiol extract from extract of cannabis (hemp)	2 – 4%	13956-29-1	None

#### Non-hazardous goods according to (EG) 1272/2008

Synonym MCT: Middle Chain Triglyceride (MCT)

1,2,3-Tricapryloylglycerol

Glycerol tricaprylate

Trioctanoin

Glycerol trioctanoate

Glyceryl tricaprylate

1,2,3-Trioctanoylglycerol

Tricaprylin

Formula: C<sub>27</sub>H<sub>50</sub>O<sub>6</sub> (averaged)

Molecular weight: 470.68 g/mol (averaged)

CAS-No.: 538-23-8 (MCT Oil)

EG-No.: 208-686-5

MCT and concentrated cannabidiol extract are mixed in a way yielding a guaranteed end concentration of Total CBD (CBD + CBDA) above 1% by weight. In accordance with the relevant legislation, no components need to be notified. Notwithstanding, the THC content has been measured. This product contains a Δ<sup>9</sup>-THC mass fraction of <0.2% according to our standardized HPLC measurement.

### SECTION 4: First Aid Measures

#### 4.1 Description of first aid measures

##### After inhalation

If inhaled, move affected person to fresh air. In case of respiratory arrest, use artificial respiration.

##### After skin contact

Wash off with soap and plenty of water.

##### After eye contact

Rinse eyes with water as a precaution.

##### After swallowing

Never instill anything through the mouth of an unconscious person. Rinse mouth with water.

#### 4.2 Most important acute or delayed symptoms and effects

The main known symptoms and effects are described on the label (see Section 2.2) and/or in Chapter 11.

#### 4.3 Information about immediate medical assistance or special treatment

Treatment is the same with cannabis overdose symptom.

## **SECTION 5: Firefighting Measures**

### **5.1 Extinguishing agents**

Suitable extinguishing media

Use water spray, alcohol-resistant foam, dry extinguishing agent or carbon dioxide.

### **5.2 Special hazards arising from the substance or mixture**

Carbon oxides

### **5.3 Instructions for fire fighting**

In case of fire, wear self-contained breathing apparatus if necessary.

## **SECTION 6: Accidental Release Measures**

### **6.1 Personal Precautions, Protective Equipment and Emergency Procedures**

Do not inhale vapors/mist/gas.

See section 8 for personal protective equipment.

### **6.2 Environmental precautions**

Do not empty into drains.

### **6.3 Methods and materials for retention and cleaning**

For disposal, place in suitable and closed containers according to the local regulations.

### **6.4 Reference to other sections**

Disposal: see section 13.

## **SECTION 7: Handling and Storage**

### **7.1 Protective measures for safe handling**

Packaging, handling of the package and its content must only be performed by a serious, trustworthy, capable, educated, certified and trained person.

User should thoroughly wash hands with soap and water after handling this material.

The MCT oil settles at low temperature, which makes the solution more compact; it can be heated in a water bath (max. 40°C) before use. Shake before use.

### **7.2 Conditions for safe storage under consideration of incompatibilities**

Store in a dry place and in a cool place (Do not store > 30°C). Protect from sunlight (UV). Keep container tightly closed in a dry, well-ventilated place. Keep out of reach of children. Close opened containers carefully and store upright to prevent any leakage.

### **7.3 Specific end uses**

No specific uses other than those mentioned in section 1.2 are foreseen.

## SECTION 8. Exposure Controls/Personal Protection

### 8.1 Parameters to be monitored

Components with work center-related limit values that are to be monitored  
Contains no substances with occupational exposure limit values.

### 8.2 Limitation and monitoring of exposure

Suitable technical control equipment

General industrial hygiene measures

Personal protective equipment:

Eye/face protection

For eye protection only use equipment that has been tested and approved according to official standards such as NIOSH (US) or EN 166 (EU).

Skin Protection

Working with gloves. Gloves must be inspected before use. Use a suitable removal method (without touching the outer surface of the glove) to avoid skin contact with this product.

Disposal of contaminated gloves after use in accordance with legal requirements.

Wash and dry hands.

The protective gloves to be used must comply with the specifications of EC Directive 89/686/EEC and the resulting EN 374 standard.

Body protection

Impermeable protective clothing, the type of protective equipment must be selected according to the concentration and quantity of the hazardous substance at the workplace.

Respiratory protection

No respiratory protection necessary. In case of disturbing emissions use respirator type OV/AG (US) or ABEK (EU EN 14387) Respiratory protective devices and components must be tested and approved in accordance with corresponding national standards such as NIOSH (US) or CEN (EU).

Environmental exposure monitoring

Do not empty into drains.

## SECTION 9: Physical and Chemical Properties

### 9.1 Information on basic physical and chemical properties

a. Appearance Shape:	liquid, viscous
Color:	golden brown
b. Odor	Aromatic, fresh, smooth
c. Odor threshold	No data available
d. pH	No data available
e. Melting point/freezing point	-5 °C – +1°C
f. Initial boiling point and boiling range	No data available
g. Flash point	No data available
h. Evaporation rate	No data available
i. Flammability (solid, gaseous)	No data available
j. Upper/lower ignition or explosion limits	No data available
k. Vapor pressure	No data available
l. Vapor density	No data available
m. Relative density	0.96 – 0.98 g / mL (25°C)

n. Water solubility	Very poorly soluble.
o. Distribution coefficient: n-octanol/water	No data available.
p. Self-ignition temperature	No data available
q. Decomposition temperature	No data available
r. Viscosity	No data available
s. Explosive properties	No data available
t. Oxidizing properties	No data available

## 9.2 Other safety information

No data available

## SECTION 10: Stability and Reactivity

### 10.1 Reactivity

No data available

### 10.2 Chemical stability

Stable under specified storage conditions.

### 10.3 Possibility of dangerous reactions

No data available

### 10.4 Conditions to avoid

No data available

### 10.5 Incompatible materials

Strong oxidizing agents

### 10.6 Hazardous decomposition products

Other decomposition products - No data available

In case of fire: see chapter 5

## SECTION 11: Toxicological Information

### 11.1 Information on toxicological effects

This product has not been tested. The active component is subject to medical research and is known to be biologically active at low concentrations.

#### Acute toxicity

Active CBD tolerated by humans orally 1500 mg/day Active CBD tolerated in mice 500 mg/kg/day over 14 days, dietary cannabidiol oral solution 100 mg/ml not considered to be sufficiently harmful to require classification for supply.

#### Etchant/irritant effect on skin

May give mild skin irritation, but not classified as irritant.

#### Severe eye damage/irritation

May be mildly irritant to the eye, but not classified as irritant.

#### Sensitization of the respiratory tract/skin

Plant extracts may produce an allergic reaction to the skin of some individuals cannabidiol oral solution 100 mg/ml has given no indications of sensitising reactions during handling or use

#### Germ cell mutagenicity

The active component is not considered to be mutagenic from preclinical in-vitro testing.

#### Carcinogenicity

The components are not classified as a carcinogen by IARC There was no evidence that administration of CBD as CBD Botanical Drug Substance (BDS) influenced tumour formation at up to 50 mg CBD/kg/day in a 2 year rat dietary carcinogenicity study.

**Reproductive toxicity**

No indication of reproductive or teratogenic effects from data derived for pre-clinical testing of active component.

**Specific target organ toxicity - single exposure**

Not expected to cause systemic effects to organs on single exposure.

**Specific target organ toxicity - repeated exposure**

Not expected to cause systemic effects to organs on repeated exposure.

**Danger of aspiration**

Not applicable. Non-hydrocarbon.

**Additional Information**

This is an active form of a medicinal product that is known to have biological effects at low concentrations. Exposure must be avoided where possible.

Acute toxicity	No data available
Etchant/irritant effect on skin	No data available
Severe eye damage/irritation	No data available
Sensitization of the respiratory tract/skin	No data available
Germ cell mutagenicity	No data available
Carcinogenicity	No data available
Reproductive toxicity	No data available
Specific target organ toxicity - single exposure	No data available
Specific target organ toxicity - repeated exposure	No data available
Danger of aspiration	No data available
Additional Information	No data available

To the best of our knowledge, the chemical, physical and toxicological properties of this natural substance/mixture have not been fully investigated.

## **SECTION 12: Ecological Information**

<b>12.1</b> Toxicity	No data available
<b>12.2</b> Persistence and degradability	No data available
<b>12.3</b> Bioaccumulation potential	No data available
<b>12.4</b> Mobility in the ground	No data available
<b>12.5</b> Results of the PBT and vPvB assessment	A PBT/vPvB assessment is not available as a chemical safety assessment is not required/not performed
<b>12.6</b> Other adverse effects	No data available

## **SECTION 13: Disposal Considerations**

### **13.1 Procedures for waste treatment**

Product: Residual quantities and non-recyclable solutions must be sent to a recognised waste disposal company or be disposed in accordance with local regulations.

Contaminated packaging: Dispose of as unused product.

## **SECTION 14: Transport Information**

Tariff Code: 1302.19.20: Extract of Cannabis.

### **13.2 Special precautions for the user**

Do not expose to a temperature higher than 30° C

## **SECTION 15: Regulatory Information**

### **14.1 Safety, health and environmental protection/legislation specific to the substance or mixture**

No data available

### **14.2 Chemical safety assessment**

No chemical safety assessment has been performed for this product.

## **SECTION 16: Other Information**

This information has been compiled to the best of our knowledge but does not claim to be complete or accurate and should be understood by the user as a guideline only. GTG Plant Factory Co., Ltd. disclaims all liability for any damage that may occur when handling or coming into contact with such packaging, ingredients or chemicals.